Senti Biosciences Inc. Reports Financial Results for Q4 and Full Year 2025

Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences, expressed pride in the team's commitment to advancing the company's mission. “2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform,” Lu stated. He highlighted the encouraging clinical data generated by the lead program, SENTI-202, and emphasized the company’s disciplined approach to execution and capital management.

Senti Biosciences has made notable strides in its clinical pipeline, particularly with SENTI-202, a therapy designed for patients with relapsed/refractory acute myeloid leukemia (AML):

As of December 31, 2025, Senti Biosciences reported cash and cash equivalents amounting to approximately $16.4 million, a significant decrease from $48.3 million recorded a year earlier. The decline is indicative of the company's ongoing investments in research and development.

For the fourth quarter of 2025, R&D expenses remained consistent at $7.8 million, matching the same quarter in 2024. For the full year, total R&D expenses amounted to $37.6 million, reflecting the company's commitment to advancing its clinical programs.

General and administrative expenses for Q4 2025 were reported at $5.8 million, down from $8.4 million in Q4 2024. This decrease of $2.6 million is attributed primarily to reductions in external services and supplies costs, although there was a slight increase in personnel-related expenses. For the full year, G&A expenses totaled $26.2 million.

Senti Biosciences reported a net loss of $14.5 million, or $0.53 per share, for the three months ended December 31, 2025. The full-year net loss stood at $61.4 million, or $2.73 per share. The annual loss includes a non-recurring $5.1 million impairment of long-lived assets and a non-cash stock-based compensation expense of $5.7 million.

Senti's balance sheet as of December 31, 2025, reflected total assets of $51.2 million and total liabilities of $45.6 million. The accumulated deficit grew to $358.6 million, a contrast to $297.1 million at the end of 2024. Stockholders' equity was reported at $5.6 million, down from $25.6 million the previous year.

With a strong focus on clinical advancement and disciplined financial management, Senti Biosciences is well-positioned to capitalize on the opportunities ahead in the evolving field of cell and gene therapies. As the company progresses with its lead program, SENTI-202, and continues to enhance its Gene Circuit platform, stakeholders will be watching closely for future developments and milestones.

Senti Biosciences is dedicated to improving the lives of patients facing serious diseases, and its innovative approach to synthetic biology may pave the way for new treatment paradigms in oncology and beyond.